The THE ROLE OF AGE AND COMORBIDITIES ON THE OUTCOME OF CONFIRMED CLINICALLY CRITICAL COVID-19 PATIENTS TREATED WITH REMDESIVIR AT INDONESIA'S NATIONAL REFERRAL HOSPITAL
Keywords:Age, Comorbidities, COVID-19, Outcome, Remdesivir
Background: There is currently no viable pharmaceutical therapy for COVID-19 illness that has been validated. The use of remdesivir is one of the medications for which there is no consistent evidence of a significant therapeutic benefit or a meaningful effect on survival.
Methods: A retrospective cohort study was used in this study. The subjects in this study were confirmed clinically critical COVID-19 patients who were treated at Dr. M Djamil Hospital Padang, one of Indonesia's national referral hospitals, from January to June 31, 2021. The number of samples in this study was 90 patients. The Chi-square test was performed in bivariate analysis, and the odds ratio was calculated. SPSS version 17.0 was used to analyze the data.
Results: The results of this study found that there was an association between ages 50-59 years (OR = 10.23, 95% CI 1.89-55.53), 60-69 years (OR = 4.58, 95% CI 1.25-16.76), and > 70 years (OR = 1.91, 95% CI 1.38 -9.59), comorbid diabetes mellitus (OR = 9.78, 95% CI 1.23-77.66), the number of comorbid > 1 (OR = 10.97, 95% CI 2.19-54.96, and the number of comorbid 1 (OR = 5.69, 95% CI 1.59- 20.41) with the outcome of confirmed clinically critical COVID-19 patients treated with remdesivir.
Conclusion: The significance of age and comorbidities on the outcome of COVID-19 patients treated with remdesivir at Indonesia's national referral hospital was confirmed in this study. This study could assist in the management of patient therapy, potentially decreasing morbidity and even patient mortality.
Afriani, A., Ermayanti, S., Medison, I., Russilawati, R., Anggrainy, F., Sabri, Y. S., and Nindrea, R. D. (2022). Survival of COVID-19 Patients Who Received Antiviral and Antiviral Therapy Combined with Anti-inflammation Therapy in a National Referral Hospital, Indonesia. Open Access Macedonian Journal of Medical Sciences, 10(B): 240–244.
Alqahtani, M. S., Abbas, M., Alsabaani, A., Alqarni, A., Almohiy, H. M., Alsawqaee, E., Alshahrani, R., and Alshahrani, S. (2022). The potential impact of COVID-19 virus on the heart and the circulatory system. Infection and Drug Resistance, 15: 1175–1189.
Babaei, F., Mirzababaei, M., Nassiri-Asl, M., and Hosseinzadeh, H. (2021). Review of registered clinical trials for the treatment of COVID-19. Drug Development Research, 82(4): 474–493.
Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., et al. (2020). Remdesivir for the Treatment of Covid-19 - Final Report. The New England Journal of Medicine, 383(19): 1813–1826.
Chalmers, J. D., Crichton, M. L., Goeminne, P. C., Cao, B., Humbert, M., Shteinberg, M., Antoniou, K. M., Ulrik, C. S., Parks, H., Wang, C., Vandendriessche, T., Qu, J., Stolz, D., Brightling, C., Welte, T., Aliberti, S., Simonds, A. K., Tonia, T., and Roche, N. (2021). Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. The European Respiratory Journal, 57(4): 2100048.
Eastman, R. T., Roth, J. S., Brimacombe, K. R., Simeonov, A., Shen, M., Patnaik, S., and Hall, M. D. (2020). Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19. ACS Central Science, 6(5): 672–683.
Kanai, O., Fujita, K., Nanba, K., Esaka, N., Hata, H., Seta, K., Yasoda, A., Odagaki, T., and Mio, T. (2021). Safety of Remdesivir for Patients 80 Years of Age or Older with Coronavirus Disease 2019 (COVID-19). Drugs & aging, 38(12): 1067–1074.
Kichloo, A., Albosta, M., Kumar, A., Aljadah, M., Mohamed, M., El-Amir, Z., Wani, F., Jamal, S., Singh, J., and Kichloo, A. (2021). Emerging therapeutics in the management of COVID-19. World Journal of Virology, 10(1): 1–29.
Li, G., and De Clercq, E. (2020). Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nature Reviews Drug Discovery, 19(3): 149–150.
Liu, J., and Liu, S. (2020). The management of coronavirus disease 2019 (COVID-19). Journal of Medical Virology, 92(9): 1484–1490.
Lotfi, M., Hamblin, M. R., and Rezaei, N (2020). COVID-19: Transmission, prevention, and potential therapeutic opportunities. Clinica Chimica Acta; International Journal of Clinical Chemistry, 508: 254–266.
Naik, R. R., and Shakya, A. K. (2021). Therapeutic Strategies in the Management of COVID-19. Frontiers in Molecular Biosciences, 7: 636738.
Nile, S. H., Nile, A., Qiu, J., Li, L., Jia, X., and Kai, G. (2020). COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons. Cytokine & Growth Factor Reviews, 53: 66–70.
Nindrea R. D. (2022). Omicron: The government of Indonesia and telemedicine services for patients in self-isolation. Asia-Pacific Journal of Public Health, 34(5): 598–599.
Pascarella, G., Strumia, A., Piliego, C., Bruno, F., Del Buono, R., Costa, F., Scarlata, S., and Agrò, F. E. (2020). COVID-19 diagnosis and management: a comprehensive review. Journal of Internal Medicine, 288(2): 192–206.
Pasquini, Z., Montalti, R., Temperoni, C., Canovari, B., Mancini, M., Tempesta, M., Pimpini, D., Zallocco, N., and Barchiesi, F. (2020). Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU. The Journal of Antimicrobial Chemotherapy, 75(11): 3359–3365.
Pasquini, Z., Montalti, R., and Barchiesi, F. (2021). Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU-authors' response. The Journal of Antimicrobial Chemotherapy, 76(6): 1651–1652.
Perrotta, F., Corbi, G., Mazzeo, G., Boccia, M., Aronne, L., D'Agnano, V., Komici, K., Mazzarella, G., Parrella, R., and Bianco, A. (2020). COVID-19 and the elderly: insights into pathogenesis and clinical decision-making. Aging Clinical and Experimental Research, 32(8): 1599–1608.
Petrie, J. R., Guzik, T. J., & Touyz, R. M. (2018). Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. The Canadian Journal of Cardiology, 34(5): 575–584.
Saguil, A., and Fargo, M. V. (2020). Acute respiratory distress syndrome: diagnosis and management. American Family Physician, 101(12): 730–738.
Singh, A. K., Singh, A., Singh, R., and Misra, A. (2020). Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies. Diabetes & Metabolic Syndrome, 14(4): 641–648.
Zheng, Z., Peng, F., Xu, B., Zhao, J., Liu, H., Peng, J., Li, Q., Jiang, C., Zhou, Y., Liu, S., Ye, C., Zhang, P., Xing, Y., Guo, H., and Tang, W. (2020). Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. The Journal of Infection, 81(2): e16–e25.
How to Cite
Copyright (c) 2023 African Journal of Infectious Diseases (AJID)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright: Creative Commons Attribution CC BY This license lets others distribute, remix, tweak, and build upon your work, even commercially, as long as they credit you for the original creation. This is the most accommodating of licenses offered. Recommended for maximum dissemination and use of licensed materials. View License Deed | View Legal Code Authors can also self-archive their manuscripts immediately and enable public access from their institution's repository. This is the version that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review and in editor-author communications.